Spruce Biosciences Q2 2026 Update: BLA Submission for TA-ERT Remains on Track for Q4 2026
SPRB has more than doubled off its 52-week low of $7 on light trading volume (0.4× avg).
Summary
Spruce Biosciences posted a Q2 2026 net loss of $16.2M with cash of $96.3M, and confirmed its BLA submission for TA-ERT is on track for Q4 2026. A $5.5M strategic investment from patient groups will fund an expanded access program.
Key Events · Earnings and Guidance · SPRB
-
Q2 2026 Financial Results
Operating expenses totaled $16.5 million, driving a net loss of $16.2 million ($6.68 per share). Cash and cash equivalents stood at $96.3 million as of June 30, 2026, which is expected to fund operations into the second half of 2027.
-
BLA Submission on Track for Q4 2026
A Biologics License Application for TA-ERT in MPS IIIB is anticipated in Q4 2026, seeking accelerated approval based on CSF HS-NRE as a surrogate endpoint.
-
Confirmatory Study to Initiate in Q4 2026
The TrAnsform confirmatory study, required for potential FDA accelerated approval, is expected to enroll approximately 14 children and evaluate the effect of TA-ERT on cognition.
-
$5.5M Strategic Investment from Patient Groups
The Cure Sanfilippo Foundation and the National MPS Society made a combined $5.5 million investment to partially fund the TA-ERT Expanded Access Program, which is expected to enroll approximately 10 participants.
Analysis · SPRB · Life Sciences
With a net loss of $16.2 million and cash of $96.3 million, Spruce Biosciences extended its runway into the second half of 2027. The company confirmed that its BLA submission for TA-ERT in MPS IIIB is on track for Q4 2026—a major regulatory milestone for a disease with no approved therapy. A $5.5 million strategic investment from patient advocacy groups will fund an expanded access program, broadening patient reach. Additionally, the confirmatory TrAnsform study, a condition for potential accelerated approval, is set to begin in Q4 2026. These updates signal execution toward a potential commercial launch next year, though the company remains pre-revenue with significant operating expenses.
At the time of this filing, SPRB was trading at $46.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.7M. The 52-week trading range was $7.00 to $240.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.